Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Clinical and Molecular Hepatology · 01.04.2023 · 29 (2) · 277-292
DOI: 10.3350/cmh.2022.0212 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2023. Verfasst von Do Young Kim und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 155-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Abbott, BMS, Gilead.
Abstract (Originalsprache)
Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent on its cut-off levels, degree of liver necroinflammation, and etiology of liver disease. Though various studies have demonstrated the utility of protein induced by vitamin K absence II (PIVKA-II) in surveillance, treatment monitoring, and predicting recurrence, it is still not recommended as a routine biomarker test. A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC, based on six predetermined statements. The experts agreed that PIVKA-II was valuable in the detection of HCC in AFP-negative patients, and could potentially benefit detection of early HCC in combination with AFP. PIVKA-II is clinically useful for monitoring curative and intra-arterial locoregional treatments, outcomes, and recurrence, and could potentially predict microvascular invasion risk and facilitate patient selection for liver transplant. However, combining PIVKA-II with US and AFP for HCC surveillance, including small HCC, still requires more evidence, whilst its role in detecting AFP-negative HCC will potentially increase as more patients are treated for hepatitis-related HCC. PIVKA-II in combination with AFP and US has a clinical role in the Asia-Pacific region for surveillance. However, implementation of PIVKA-II in the region will have some challenges, such as requiring standardization of cut-off values, its cost-effectiveness and improving awareness among healthcare providers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Clinical Pathology Department, Medic Center, Ho Chi Minh, Vietnam.
- Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore.
- Faculty of Medicine, University Indonesia/Ciptomangunkusumo Hospital, Jakarta, Indonesia.
- Clinical Pathology Department, Integrated Laboratory, Dharmais National Cancer Hospital, Jakarta, Indonesia.
- Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Förderung
- Abbott
- BMS
- Gilead
- Merck
- AMiLi
- MiRXES
- Perspectum
- Roche
Zitieren
APA
Kim, D. Y., Toan, B. N., Tan, C. K., Hasan, I., Setiawan, L., Yu, M. L., Izumi, N., Huyen, N. N., Chow, P. K., Mohamed, R., Chan, S. L., Tanwandee, T., Lee, T. Y., Hai, T. T. N., Yang, T., Lee, W. C., & Chan, H. L. Y. (2023). Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clinical and Molecular Hepatology, 29(2), 277-292. https://doi.org/10.3350/cmh.2022.0212
Vancouver
Kim DY, Toan BN, Tan CK, Hasan I, Setiawan L, Yu ML, et al. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clinical and Molecular Hepatology. 2023;29(2):277-292. doi:10.3350/cmh.2022.0212
BibTeX
@article{Kim2023,
author = {Kim, Do Young and Toan, Bao Nguyen and Tan, Chee-Kiat and Hasan, Irsan and Setiawan, Lyana and Yu, Ming-Lung and Izumi, Namiki and Huyen, Nguyen Nguyen and Chow, Pierce Kah-Hoe and Mohamed, Rosmawati and Chan, Stephen Lam and Tanwandee, Tawesak and Lee, Teng-Yu and Hai, Thi Thanh Nguyen and Yang, Tian and Lee, Woo-Chang and Chan, Henry Lik Yuen},
title = {Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region},
journal = {Clinical and Molecular Hepatology},
year = {2023},
volume = {29},
number = {2},
pages = {277--292},
doi = {10.3350/cmh.2022.0212}
}
EUVIMED